AAPL294.31+0.01 (+0.00%) ▲|ABBV235.75+0.99 (+0.42%) ▲|ABT91.40+0.87 (+0.96%) ▲|ACN130.94+3.93 (+3.09%) ▲|ADBE197.85+0.42 (+0.21%) ▲|AMAT572.52-13.36 (-2.28%) ▼|AMD508.48-11.38 (-2.19%) ▼|AMGN353.24+6.23 (+1.79%) ▲|AMT176.42-2.96 (-1.65%) ▼|AMZN237.06+2.95 (+1.26%) ▲|AVGO378.38-1.77 (-0.47%) ▼|AXP343.00+5.22 (+1.55%) ▲|BA221.07+4.36 (+2.01%) ▲|BAC57.77-0.15 (-0.25%) ▼|BKNG184.50+15.56 (+9.21%) ▲|BLK988.67-26.67 (-2.63%) ▼|BMY55.34-0.19 (-0.34%) ▼|BNY144.54-2.75 (-1.87%) ▼|BRK-B497.12+4.31 (+0.87%) ▲|C144.01-0.96 (-0.66%) ▼|CAT981.87-2.37 (-0.24%) ▼|CL92.71+1.28 (+1.39%) ▲|CMCSA22.74-0.06 (-0.26%) ▼|COF201.78+3.97 (+2.00%) ▲|COP107.01-2.96 (-2.69%) ▼|COST963.90+6.22 (+0.65%) ▲|CRM153.22-0.20 (-0.13%) ▼|CSCO119.21-1.94 (-1.60%) ▼|CVS101.33-0.24 (-0.24%) ▼|CVX171.84-4.15 (-2.36%) ▼|DE608.40+16.46 (+2.78%) ▲|DHR188.62+9.65 (+5.39%) ▲|DIS102.23-1.31 (-1.26%) ▼|DUK126.21+1.16 (+0.93%) ▲|EMR141.69-1.45 (-1.01%) ▼|FDX312.42-4.82 (-1.52%) ▼|GD346.49-3.85 (-1.10%) ▼|GE367.07+10.60 (+2.97%) ▲|GEV1,052.12+17.14 (+1.66%) ▲|GILD125.92+0.87 (+0.70%) ▲|GM79.56+0.61 (+0.77%) ▲|GOOG342.82-3.26 (-0.94%) ▼|GOOGL343.37-2.72 (-0.79%) ▼|GS1,076.97-17.47 (-1.60%) ▼|HD342.39+17.94 (+5.53%) ▲|HON227.43+5.06 (+2.28%) ▲|IBM263.09-1.85 (-0.70%) ▼|INTC129.50-2.79 (-2.11%) ▼|INTU266.54+8.49 (+3.29%) ▲|ISRG403.09-0.10 (-0.02%) ▼|JNJ240.69+1.61 (+0.67%) ▲|JPM333.46-0.68 (-0.20%) ▼|KO81.02+0.71 (+0.88%) ▲|LIN518.88+6.62 (+1.29%) ▲|LLY1,113.83+6.75 (+0.61%) ▲|LMT496.42-7.25 (-1.44%) ▼|LOW221.86+8.32 (+3.90%) ▲|LRCX364.09-7.24 (-1.95%) ▼|MA496.94+8.87 (+1.82%) ▲|MCD275.42+3.76 (+1.38%) ▲|MDLZ62.16+1.10 (+1.80%) ▲|MDT80.77+0.14 (+0.17%) ▲|META559.66-2.54 (-0.45%) ▼|MMM166.39+4.55 (+2.81%) ▲|MO72.22+0.61 (+0.85%) ▲|MRK121.26+1.66 (+1.39%) ▲|MS220.78-5.26 (-2.32%) ▼|MSFT368.77-5.17 (-1.38%) ▼|MU1,015.70-36.07 (-3.43%) ▼|NEE87.43+1.00 (+1.15%) ▲|NFLX72.36-0.46 (-0.63%) ▼|NKE41.75-0.63 (-1.48%) ▼|NOW93.85-2.10 (-2.18%) ▼|NVDA197.51-2.50 (-1.25%) ▼|ORCL156.11-9.05 (-5.48%) ▼|PEP142.99+0.94 (+0.66%) ▲|PFE24.15-0.58 (-2.33%) ▼|PG152.77+1.91 (+1.27%) ▲|PLTR113.37-3.33 (-2.85%) ▼|PM179.21+0.52 (+0.29%) ▲|QCOM193.45-10.69 (-5.23%) ▼|RTX186.71+0.32 (+0.17%) ▲|SBUX104.37+3.32 (+3.29%) ▲|SCHW91.45-1.73 (-1.85%) ▼|SO95.46+0.53 (+0.55%) ▲|SPG222.29+5.55 (+2.56%) ▲|T22.47-0.35 (-1.51%) ▼|TMO490.94+21.59 (+4.60%) ▲|TMUS183.00-1.57 (-0.85%) ▼|TSLA374.75-6.86 (-1.80%) ▼|TXN303.03-1.33 (-0.44%) ▼|UBER74.13+4.46 (+6.40%) ▲|UNH403.76-5.49 (-1.34%) ▼|UNP260.33+1.72 (+0.67%) ▲|UPS105.39-0.44 (-0.42%) ▼|USB60.22+0.17 (+0.27%) ▲|V333.23+4.75 (+1.45%) ▲|VZ45.81-0.92 (-1.97%) ▼|WFC84.40+0.27 (+0.32%) ▲|WMT119.72+0.30 (+0.25%) ▲|XOM136.30-3.43 (-2.45%) ▼|AAPL294.31+0.01 (+0.00%) ▲|ABBV235.75+0.99 (+0.42%) ▲|ABT91.40+0.87 (+0.96%) ▲|ACN130.94+3.93 (+3.09%) ▲|ADBE197.85+0.42 (+0.21%) ▲|AMAT572.52-13.36 (-2.28%) ▼|AMD508.48-11.38 (-2.19%) ▼|AMGN353.24+6.23 (+1.79%) ▲|AMT176.42-2.96 (-1.65%) ▼|AMZN237.06+2.95 (+1.26%) ▲|AVGO378.38-1.77 (-0.47%) ▼|AXP343.00+5.22 (+1.55%) ▲|BA221.07+4.36 (+2.01%) ▲|BAC57.77-0.15 (-0.25%) ▼|BKNG184.50+15.56 (+9.21%) ▲|BLK988.67-26.67 (-2.63%) ▼|BMY55.34-0.19 (-0.34%) ▼|BNY144.54-2.75 (-1.87%) ▼|BRK-B497.12+4.31 (+0.87%) ▲|C144.01-0.96 (-0.66%) ▼|CAT981.87-2.37 (-0.24%) ▼|CL92.71+1.28 (+1.39%) ▲|CMCSA22.74-0.06 (-0.26%) ▼|COF201.78+3.97 (+2.00%) ▲|COP107.01-2.96 (-2.69%) ▼|COST963.90+6.22 (+0.65%) ▲|CRM153.22-0.20 (-0.13%) ▼|CSCO119.21-1.94 (-1.60%) ▼|CVS101.33-0.24 (-0.24%) ▼|CVX171.84-4.15 (-2.36%) ▼|DE608.40+16.46 (+2.78%) ▲|DHR188.62+9.65 (+5.39%) ▲|DIS102.23-1.31 (-1.26%) ▼|DUK126.21+1.16 (+0.93%) ▲|EMR141.69-1.45 (-1.01%) ▼|FDX312.42-4.82 (-1.52%) ▼|GD346.49-3.85 (-1.10%) ▼|GE367.07+10.60 (+2.97%) ▲|GEV1,052.12+17.14 (+1.66%) ▲|GILD125.92+0.87 (+0.70%) ▲|GM79.56+0.61 (+0.77%) ▲|GOOG342.82-3.26 (-0.94%) ▼|GOOGL343.37-2.72 (-0.79%) ▼|GS1,076.97-17.47 (-1.60%) ▼|HD342.39+17.94 (+5.53%) ▲|HON227.43+5.06 (+2.28%) ▲|IBM263.09-1.85 (-0.70%) ▼|INTC129.50-2.79 (-2.11%) ▼|INTU266.54+8.49 (+3.29%) ▲|ISRG403.09-0.10 (-0.02%) ▼|JNJ240.69+1.61 (+0.67%) ▲|JPM333.46-0.68 (-0.20%) ▼|KO81.02+0.71 (+0.88%) ▲|LIN518.88+6.62 (+1.29%) ▲|LLY1,113.83+6.75 (+0.61%) ▲|LMT496.42-7.25 (-1.44%) ▼|LOW221.86+8.32 (+3.90%) ▲|LRCX364.09-7.24 (-1.95%) ▼|MA496.94+8.87 (+1.82%) ▲|MCD275.42+3.76 (+1.38%) ▲|MDLZ62.16+1.10 (+1.80%) ▲|MDT80.77+0.14 (+0.17%) ▲|META559.66-2.54 (-0.45%) ▼|MMM166.39+4.55 (+2.81%) ▲|MO72.22+0.61 (+0.85%) ▲|MRK121.26+1.66 (+1.39%) ▲|MS220.78-5.26 (-2.32%) ▼|MSFT368.77-5.17 (-1.38%) ▼|MU1,015.70-36.07 (-3.43%) ▼|NEE87.43+1.00 (+1.15%) ▲|NFLX72.36-0.46 (-0.63%) ▼|NKE41.75-0.63 (-1.48%) ▼|NOW93.85-2.10 (-2.18%) ▼|NVDA197.51-2.50 (-1.25%) ▼|ORCL156.11-9.05 (-5.48%) ▼|PEP142.99+0.94 (+0.66%) ▲|PFE24.15-0.58 (-2.33%) ▼|PG152.77+1.91 (+1.27%) ▲|PLTR113.37-3.33 (-2.85%) ▼|PM179.21+0.52 (+0.29%) ▲|QCOM193.45-10.69 (-5.23%) ▼|RTX186.71+0.32 (+0.17%) ▲|SBUX104.37+3.32 (+3.29%) ▲|SCHW91.45-1.73 (-1.85%) ▼|SO95.46+0.53 (+0.55%) ▲|SPG222.29+5.55 (+2.56%) ▲|T22.47-0.35 (-1.51%) ▼|TMO490.94+21.59 (+4.60%) ▲|TMUS183.00-1.57 (-0.85%) ▼|TSLA374.75-6.86 (-1.80%) ▼|TXN303.03-1.33 (-0.44%) ▼|UBER74.13+4.46 (+6.40%) ▲|UNH403.76-5.49 (-1.34%) ▼|UNP260.33+1.72 (+0.67%) ▲|UPS105.39-0.44 (-0.42%) ▼|USB60.22+0.17 (+0.27%) ▲|V333.23+4.75 (+1.45%) ▲|VZ45.81-0.92 (-1.97%) ▼|WFC84.40+0.27 (+0.32%) ▲|WMT119.72+0.30 (+0.25%) ▲|XOM136.30-3.43 (-2.45%) ▼|
27.5 C
New York
Wednesday, June 24, 2026

Tag: FDA

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (SRPT)

NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”).

Theranos Makes a Big Bang at the FDA

PALM BEACH, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- Today marks a significant milestone for theranos and its diagnostic technology. The theranos system performs automated sample processing and analysis to produce clinical test results. The U.S. Food and Drug Administration’s Center for Devices and Radiological Health (CDRH) has affirmed that the core technology is not under question.

ROSEN, LEADING TRIAL ATTORNEYS, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPG

NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”), of the important August 8, 2025 lead plaintiff deadline.

INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Boca Raton, Florida, June 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has entered into securities purchase agreements with two healthcare focused institutional investors for the purchase and sale of 3,000,000 shares of its common stock in a registered direct offering (the "Offering") at a purchase price of $6.30 per share, priced at-the-market under Nasdaq rules.

Ophthalmology Drugs Market worth $26.28 billion by 2030 with 6.1% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., June 27, 2025 /PRNewswire/ -- The global Ophthalmology Drugs Market , valued at US$18.34 billion in 2024 stood at US$19.52 billion in 2025...

Ophthalmology Drugs Market worth $26.28 billion by 2030 with 6.1% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., June 27, 2025 /PRNewswire/ -- The global Ophthalmology Drugs Market , valued at US$18.34 billion in 2024 stood at US$19.52 billion in 2025...

GC Biopharma USA Highlights Innovative Manufacturing Approach to IVIG Safety at 2025 CIS Annual Meeting

Differences in manufacturing processes impact the tolerability of intravenous immune globulin (IVIG) products GC Biopharma's manufacturing process reduces FXIa to undetectable levels – a critical...

Synthego Gains Approval to Proceed with Sale to Perceptive Advisors; Transaction Set to Close in July

Synthego Solidly Positioned for Expansion & Growth REDWOOD CITY, Calif., June 26, 2025 /PRNewswire/ -- Synthego, a leading provider of CRISPR solutions, today confirmed...

PEPG Investors Have the Opportunity to Lead the PepGen Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PepGen To Contact Him Directly To Discuss...

Prism Pain and Wellness Offering Novel Brain Stimulation to Treat Depression and Optimize Mental Health

ENGLEWOOD, Colo., June 26, 2025 /PRNewswire/ -- The pinnacle of medication-free wellness is now available for those struggling with depression, anxiety and mental fog....

Pendopharm® and KalVista® Partner to Bring First Oral On-Demand HAE Treatment to Canada

MONTREAL, June 26, 2025 /CNW/ - Pendopharm®, a division of Pharmascience Inc., has entered into an exclusive distribution agreement with KalVista Pharmaceuticals, Inc. (NASDAQ:...

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

Global Cancer Immunotherapy Market Projected to Reach $247 Billion by 2029, Driven by 11.4% CAGR

"Harnessing the Power of the Immune System: How Cancer Immunotherapy and Oncolytic Virology Are Reshaping the Future of Oncology in a Digitally Driven Era" BOSTON,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsFDA